Monitor future Form 4 filings for actual option exercises or share transactions by Rebecca Chambers, which could signal insider sentiment. The Power of Attorney simplifies compliance but does not imply imminent trading activity.
Price Chart
Executive Summary
Rebecca Chambers, a director or officer of Alamar Biosciences, filed a Form 3 to report initial beneficial ownership of securities, including a stock option to purchase 140,612 shares of Class B common stock at $7.60 per share, vesting over four years. The filing also includes a Power of Attorney authorizing company executives to file Section 16 reports on her behalf. This is a routine initial ownership disclosure with no immediate financial impact.
Key Facts
- Rebecca Chambers filed Form 3 as a director or officer of Alamar Biosciences (ALMR).
- She holds a stock option to purchase 140,612 shares of Class B common stock at $7.60 per share, exercisable until 2036.
- The option vests 25% on January 15, 2027, and 1/48th monthly thereafter, subject to continuous service.
- A Power of Attorney was granted to four company executives (Timothy White, Justin J. McAnear, Mike Seater, Jessie Wang) to file Forms 3, 4, and 5 on her behalf.
- No actual shares are currently owned; only a derivative security (stock option) is reported.
Financial Impact
No immediate financial impact. Potential future dilution of approximately 140,612 shares if option is exercised.
Risk Factors
- Potential share dilution if the option is exercised.
- No risk of immediate insider selling, as no shares are currently held.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001823563-26-000011 |
| Document: 0001823563-26-000011-index-headers.html | 0001823563-26-000011 |
| Document: 0001823563-26-000011-index.html | 0001823563-26-000011 |
| Document: 0001823563-26-000011.txt | 0001823563-26-000011 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 144 | $27.42 | awaiting T+60 | — | $31.93 (−16.45%) |
Oct 14, 2026 12d ago | 144 | $27.42 | awaiting T+60 | — | $31.93 (−16.45%) |
Oct 14, 2026 12d ago | 144 | $27.42 | awaiting T+60 | — | $31.93 (+16.45%) |
Oct 5, 2026 22d ago | Press Release | $32.26 | awaiting T+60 | — | $31.93 (−1.02%) |
Sep 24, 2026 4w ago | Press Release | $32.80 | awaiting T+60 | — | $31.93 (−2.65%) |
Sep 1, 2026 8w ago | 8-K | $30.49 | awaiting T+60 | — | $31.93 (+4.72%) |
Aug 10, 2026 11w ago | 8-K | $36.57 | awaiting T+60 | — | $31.93 (−12.69%) |
Jul 13, 2026 15w ago | Press Release | $27.40 $32.26 | ▲ +17.74% | ▲ +13.74% | $31.93 (+16.53%) |
Jul 10, 2026 15w ago | Press Release | $28.42 $38.13 | ▲ +34.17% | ▲ +31.53% | $31.93 (+12.35%) |
May 8, 2026 24w ago | 8-K | $23.96 $27.11 | ▲ +13.15% | ▲ +8.31% | $31.93 (+33.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers